Xenon Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XENE research report →
Companywww.xenon-pharma.com
Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
- CEO
- Andrea DiFabio
- IPO
- 2014
- Employees
- 316
- HQ
- Burnaby, BC, CA
Price Chart
Valuation
- Market Cap
- $4.32B
- P/E
- -12.46
- P/S
- 0.00
- P/B
- 3.57
- EV/EBITDA
- -9.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -49.23%
- ROIC
- -30.44%
Growth & Income
- Revenue
- $7.50M · 0.00%
- Net Income
- $-345,910,000 · -47.62%
- EPS
- $-4.36 · -44.85%
- Op Income
- $-373,070,000
- FCF YoY
- -51.75%
Performance & Tape
- 52W High
- $63.95
- 52W Low
- $28.19
- 50D MA
- $56.42
- 200D MA
- $44.75
- Beta
- 0.65
- Avg Volume
- 1.41M
Get TickerSpark's AI analysis on XENE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | GANNON STEVEN | other | 3,500 |
| May 12, 26 | GANNON STEVEN | other | 3,500 |
| Mar 12, 26 | KENNEY CHRISTOPHER JOHN | other | 3,750 |
| Mar 12, 26 | KENNEY CHRISTOPHER JOHN | other | 3,750 |
| Mar 13, 26 | KENNEY CHRISTOPHER JOHN | sell | 1,410 |
| Mar 12, 26 | DiFabio Andrea | other | 3,750 |
| Mar 12, 26 | DiFabio Andrea | other | 3,750 |
| Mar 13, 26 | DiFabio Andrea | sell | 1,342 |
| Mar 12, 26 | MORTIMER IAN | other | 12,500 |
| Mar 12, 26 | MORTIMER IAN | other | 12,500 |
Our XENE Coverage
We haven't published any research on XENE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XENE Report →